SmithKline Pharma: A weak prescription - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

SmithKline Pharma: A weak prescription

Jun 15, 2000

SmithKline Beecham has been undergoing a tough time since the last 12 months. The 38% duty on Engerix its Hepatitis B vaccine coupled with the price control imposed on its B complex vitamin Zevit put paid to the topline growth over the last year. Its flagship brand Iodex continues to face tough competition from the likes of Paras Pharma’s ‘Moov’, Elder Pharma’s ‘Tiger Balm’ and ‘Amritanjan’.

There have been press reports in the past that the company is introducing its new anti–meningitis vaccine via its 100% subsidiary SmithKline Beecham Asia. Interestingly, this company has no manufacturing facility. Thus it even gets Crocin and Eno (the two other brands under its control) manufactured by SmithKline Pharma which derives a manufacturing fee for the same.

At present, however there are unconfirmed reports of ‘Avandia’ its block buster anti–diabetes drug being introduced through SmithKline Beecham Asia. If these turn out to be true the only source for the company to improve its topline would also vanish.

Particulars (Rs m) FY99 FY00E
Sales 3,295.0 2,636.0
Net Profit 247.0 129.0
EPS (Rs) 8.4 4.4
P/E   33.6

Though the overall pharmaceutical sector is likely to grow by at least 10%, SmithKline Pharma’s topline is expected to show a de–growth of 20% in the current year. The stock quotes at a price of Rs 147 (Rs 445/128) and is unlikely to fly, unless the parent introduces new products through its listed subsidiary.

Equitymaster requests your view! Post a comment on "SmithKline Pharma: A weak prescription". Click here!


More Views on News

Sorry! There are no related views on news for this company/sector.

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


  • Track your investment in SMITHKLINE PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks